Ginkgo Biloba Is A Unique Tree Species In China And Is Widely Planted. We Have Collaborated With The Institute Of Traditional Chinese Medicine Of The Chinese Academy Of Chinese Medical Sciences To Conduct Systematic Research On Ginkgo Biloba Leaf Resources, Quality Ecology, Genomics, Etc. In China, And Use This To Guide The Selection And Breeding Of High-quality Ginkgo Biloba Leaves, Standardized Planting, And Establish A Traceable System For Ginkgo Biloba Leaves.

At Present, More Than 160 Substances Have Been Discovered In The Leaves, Fruits, And Root Bark Of Ginkgo Biloba. We Have Collaborated With Research Teams From Sichuan Academy Of Traditional Chinese Medicine And Other Research Institutes To Conduct More Than 10 Years Of Research On The Structural Characteristics, Pharmacological Properties, Pharmacological Effects, Mechanism Targets, And Toxicological Characteristics Of Dozens Of Ginkgo Flavonoids, Ginkgo Terpenoids, And Ginkgolic Acids. All Inventions And Discoveries Have Been Protected Through Various Intellectual Property Means, Establishing A Three-dimensional Intellectual Property System.

Ginkgo Terpenoid Lactones Have A Unique "cage Like Molecular Structure", Which Is Insoluble In Water And Difficult To Dissolve In Organic Solvents. This Has Always Been A Global Challenge That Restricts The Production And Application Of Such Substances. Our Research Team Spent 5 Years Screening More Than 100 Organic Solvents That Meet The Needs Of China's Pharmaceutical Industrialization From Nearly 3000 Organic Solvents. After Tens Of Thousands Of Experiments, We Obtained High-purity Ginkgo Lactones And Solved The Problem Of Formulation Of Ginkgo Terpenoid Lactones. The Industrial Extraction, Purification And Preparation Technology Of Ginkgo Terpene Lactones Are Progressiveness.

We Have Been On The Path Of Evidence-based Medicine For Ginkgolide Drugs For More Than 10 Years, With Tens Of Thousands Of Research Cases And Over 140 Clinical Studies Conducted.

Important Clinical Studies On Ischemic Stroke Include: Phase I-III Clinical Studies, Phase IV Clinical Studies (3652 Cases), Key Drug Safety Monitoring (nested Control) (10000 Cases), GISAA Studies (945 Cases), GIANT Studies (1113 Cases), Multiple Pharmacoeconomic Studies, Exploratory Clinical Studies, Etc.